[go: up one dir, main page]

MX2025000730A - Inhibidores de proteinas de fusion de klk5 - Google Patents

Inhibidores de proteinas de fusion de klk5

Info

Publication number
MX2025000730A
MX2025000730A MX2025000730A MX2025000730A MX2025000730A MX 2025000730 A MX2025000730 A MX 2025000730A MX 2025000730 A MX2025000730 A MX 2025000730A MX 2025000730 A MX2025000730 A MX 2025000730A MX 2025000730 A MX2025000730 A MX 2025000730A
Authority
MX
Mexico
Prior art keywords
klk5
fusion protein
protein inhibitors
kallikrein
polypeptides
Prior art date
Application number
MX2025000730A
Other languages
English (en)
Inventor
Yarlagadda S Babu
Xilin Chen
Original Assignee
Biocryst Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocryst Pharm Inc filed Critical Biocryst Pharm Inc
Publication of MX2025000730A publication Critical patent/MX2025000730A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se describen polipéptidos que son útiles para, entre otras cosas, inhibir o suprimir la actividad de una proteasa relacionada con calicreína y, por lo tanto, tratar enfermedades y afecciones que implican una actividad de proteasa relacionada con calicreína desregulada. También se proporcionan composiciones farmacéuticas y métodos terapéuticos que utilizan los polipéptidos y composiciones farmacéuticas.
MX2025000730A 2022-07-20 2025-01-17 Inhibidores de proteinas de fusion de klk5 MX2025000730A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263390780P 2022-07-20 2022-07-20
PCT/US2023/028123 WO2024020083A2 (en) 2022-07-20 2023-07-19 Fusion protein inhibitors of klk5

Publications (1)

Publication Number Publication Date
MX2025000730A true MX2025000730A (es) 2025-03-07

Family

ID=89618462

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2025000730A MX2025000730A (es) 2022-07-20 2025-01-17 Inhibidores de proteinas de fusion de klk5

Country Status (15)

Country Link
US (1) US20260028389A1 (es)
EP (1) EP4561611A2 (es)
JP (1) JP2025526298A (es)
KR (1) KR20250040986A (es)
CN (1) CN119585302A (es)
AR (1) AR129973A1 (es)
AU (1) AU2023310874A1 (es)
CA (1) CA3262721A1 (es)
CL (1) CL2025000140A1 (es)
IL (1) IL318371A (es)
MA (1) MA71634A (es)
MX (1) MX2025000730A (es)
TW (1) TW202404995A (es)
UY (1) UY40359A (es)
WO (1) WO2024020083A2 (es)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190078160A1 (en) * 2017-04-21 2019-03-14 Genentech, Inc. Use of klk5 antagonists for treatment of a disease
TW202126698A (zh) * 2019-09-18 2021-07-16 美商建南德克公司 抗ｋｌｋ７抗體、抗ｋｌｋ５抗體、多重特異性抗ｋｌｋ５／ｋｌｋ７抗體、及使用方法

Also Published As

Publication number Publication date
AU2023310874A1 (en) 2025-02-27
CL2025000140A1 (es) 2025-05-16
US20260028389A1 (en) 2026-01-29
KR20250040986A (ko) 2025-03-25
CA3262721A1 (en) 2024-01-25
EP4561611A2 (en) 2025-06-04
WO2024020083A2 (en) 2024-01-25
UY40359A (es) 2024-02-15
CN119585302A (zh) 2025-03-07
MA71634A (fr) 2025-05-30
TW202404995A (zh) 2024-02-01
IL318371A (en) 2025-03-01
AR129973A1 (es) 2024-10-16
WO2024020083A3 (en) 2024-03-14
JP2025526298A (ja) 2025-08-13

Similar Documents

Publication Publication Date Title
MX2023009521A (es) Compuesto de quinazolina para inducir la degradacion de la proteina kras mutante g12d.
JOP20220083A1 (ar) حلقات غير متجانسة ثنائية الحلقة كمثبطات لـ fgfr
PH12022550399A1 (en) MTA-Cooperative PRMT5 Inhibitors
EP4438114A3 (en) Methods of making bempedoic acid and compositions of the same
MX2023012981A (es) Compuestos para inhibir o degradar proteinas objetivo, composiciones que los comprenden, metodos para su preparacion y metodos para usarlos.
DE69427127D1 (de) Substituierte tetra- und pentapeptid hemmstoffe der farnesyl protein transferase
MXPA02012272A (es) Compuestos heterociclicos que son inhibidores de la enzima dipeptidilpeptidasa-iv.
MX2021007948A (es) Inhibidores de proteina de activacion de fibroblastos.
WO2019135159A3 (en) Single-domain antibody-cytosine deaminase fusion proteins
WO2022256500A3 (en) Dll3 targeting trispecific proteins and methods of use
WO2021181233A3 (en) Cd80-fc fusion protein and uses thereof
MX2025005941A (es) Moduladores de la actividad tnf-\03b1
WO2020198695A8 (en) Compositions, devices and methods for factor vii therapy
EP4085918A4 (en) PHARMACEUTICAL COMPOSITION FOR TREATING CANCER WITH IMMUNE CHECKPOINT INHIBITOR AND FUSION PROTEIN WITH IL-2 PROTEIN AND CD80 PROTEIN
MX2023005971A (es) Metodos y composicion para las modificaciones de kras.
MX2022010748A (es) Metodos para tratar la glomeruloesclerosis segmentaria focal dependiente de apolipoproteina l1 (apol-1).
WO2022175746A8 (en) Tyk2 inhibitors and uses thereof
MX2024014262A (es) Inhibidores de parg
WO2023201299A8 (en) Pharmaceutical compositions of therapeutic proteins and methods of use
MX2022006052A (es) Inhibidores de la caspasa 6 y usos de los mismos.
WO2020068950A8 (en) Hdac1,2 inhibitors
MX2023005913A (es) Derivados de bencenosulfonamida y usos de los mismos.
WO2021191689A3 (en) Treatment of inflammatory diseases with peptides and pharmaceutical compositions
PH12021551372A1 (en) Human alpha-galactosidase variants
MX2025000730A (es) Inhibidores de proteinas de fusion de klk5